Abstract
Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer
Volume: 14 Issue: 1
Author(s): Joshua C. Doloff and David J. Waxman
Affiliation:
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Abstract: Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Export Options
About this article
Cite this article as:
Doloff C. Joshua and Waxman J. David, Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990309
DOI https://dx.doi.org/10.2174/18715206113139990309 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Nuclear Factor-κB in Inflammatory Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens
Current Stem Cell Research & Therapy Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Subject Index to Volume 3
Current Gene Therapy MicroRNA in Cervical Carcinogenesis: Window of Therapeutic Potential
Current Women`s Health Reviews FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design In Silico Identification of Natural Lead Molecules from the Genus of Phyllanthus Against Hepatitis B Virus Reverse Transcriptase
The Natural Products Journal Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [ Hot Topic: Therapeutic Potential of Peptide Motifs - Part III (Executive Editor: Jean-Claude Herve) ]
Current Pharmaceutical Design The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Current Drug Targets Long Non-coding RNA and microRNAs as Novel Potential Biomarker and Therapeutic Target in the Treatment of Gastrointestinal Cancers
Current Pharmaceutical Design Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Old and New Approaches to Target the Hsp90 Chaperone
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Antioxidants Countermeasures Against Sulfur Mustard
Mini-Reviews in Medicinal Chemistry